For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Caredx Inc (NASDAQ: CDNA) closed at $13.53 up 1.50% from its previous closing price of $13.33. In other words, the price has increased by $1.50 from its previous closing price. On the day, 0.89 million shares were traded. CDNA stock price reached its highest trading level at $13.791 during the session, while it also had its lowest trading level at $13.2927.
Ratios:
For a deeper understanding of Caredx Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.87 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 60.62. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 3.30. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On January 15, 2025, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight and also lowered its target price recommendation from $28 to $24. On August 28, 2024, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $28.Wells Fargo initiated its Underweight rating on August 28, 2024, with a $28 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 05 ’25 when Novack Jeffrey Adam sold 2,688 shares for $12.79 per share. The transaction valued at 34,381 led to the insider holds 112,930 shares of the business.
Jeffrey Adam Novack bought 2,688 shares of CDNA for $33,869 on Aug 05 ’25. On Jul 07 ’25, another insider, Maag Peter, who serves as the Director of the company, sold 10,000 shares for $18.58 each. As a result, the insider received 185,831 and left with 308,846 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDNA now has a Market Capitalization of 720159936 and an Enterprise Value of 563027584. As of this moment, Caredx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.25. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.11 while its Price-to-Book (P/B) ratio in mrq is 2.20. Its current Enterprise Value per Revenue stands at 1.652 whereas that against EBITDA is -19.761.
Stock Price History:
The Beta on a monthly basis for CDNA is 2.37, which has changed by -0.5313474 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, CDNA has reached a high of $32.97, while it has fallen to a 52-week low of $10.96. The 50-Day Moving Average of the stock is -3.81%, while the 200-Day Moving Average is calculated to be -27.65%.
Shares Statistics:
For the past three months, CDNA has traded an average of 1.61M shares per day and 1659050 over the past ten days. A total of 53.22M shares are outstanding, with a floating share count of 49.48M. Insiders hold about 6.74% of the company’s shares, while institutions hold 103.47% stake in the company. Shares short for CDNA as of 1756425600 were 6904310 with a Short Ratio of 4.29, compared to 1753920000 on 6181022. Therefore, it implies a Short% of Shares Outstanding of 6904310 and a Short% of Float of 13.28.
Earnings Estimates
The current rating of Caredx Inc (CDNA) is the result of assessments by 6.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.2, with high estimates of $0.23 and low estimates of $0.17.
Analysts are recommending an EPS of between $0.57 and $0.48 for the fiscal current year, implying an average EPS of $0.54. EPS for the following year is $0.8, with 6.0 analysts recommending between $0.93 and $0.73.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $95.25M this quarter.It ranges from a high estimate of $96.52M to a low estimate of $93.7M. As of the current estimate, Caredx Inc’s year-ago sales were $82.88MFor the next quarter, 8 analysts are estimating revenue of $102.26M. There is a high estimate of $103.9M for the next quarter, whereas the lowest estimate is $101.42M.
A total of 8 analysts have provided revenue estimates for CDNA’s current fiscal year. The highest revenue estimate was $370.9M, while the lowest revenue estimate was $367.11M, resulting in an average revenue estimate of $368.86M. In the same quarter a year ago, actual revenue was $333.79MBased on 8 analysts’ estimates, the company’s revenue will be $412.73M in the next fiscal year. The high estimate is $425.48M and the low estimate is $394.4M.
